Does Prolia reduce fractures and strengthen bones?
In a 3-year clinical trial involving women with postmenopausal osteoporosis, Prolia reduced the risk of new vertebral fractures by a significant 68% compared to a placebo. This monoclonal antibody works by inhibiting bone resorption, and clinical evidence strongly indicates that **Prolia does reduce fractures** in at-risk populations.